Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
From BioCentury This Week · · 44 min
This plays from the publisher's own server. We do not host a copy.
Description
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASDAQ. On the latest BioCentury This Week, BioCentury’s analysts discuss Eli Lilly's $3.25 billion takeout (https://www.biocentury.com/article/659178) of in vivo CAR T company Kelonia, the market debut (https://www.biocentury.com/article/659170) by obesity play Kailera and an upsized follow-on by Revolution on the back of its pancreatic cancer data. The analysts also discuss how autoimmune T cell engagers (https://www.biocentury.com/article/659151) are diverging from their oncology roots and the potential implications of President Donald Trump’s executive order on psychedelic therapies. BioCentury’s analysts also take time to remember (https://www.biocentury.com/article/659116) Sofinnova Partners’ Denis Lucquin, father of French biotech. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech (https://www.iqviabiotech.com/).
View full story: https://www.biocentury.com/article/659183
#BiotechMA #BiotechIPO #CART #TCellEngagers #PsychedelicMedicine
00:01 - Sponsor Message: IQVIA Biotech 04:20 - Lilly's Kelonia Buy 10:31 - T Cell Engagers 23:07 - Psychedelics Executive Order 35:14 - CBER Director Search 37:37 - Public Markets Roundup 42:14 - Remembering Denis Lucquin
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)